Exhibit 99.2

     Restore Vision & Clarity  Ocuphire Corporate Presentation  November 15, 2021  Mina Sooch CEO  Exhibit 99.2 
 
 2  Disclosures and Forward Looking Statements  This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements concerning Ocuphire Pharma, Inc.’s (“Ocuphire” or the “Company”) product candidates and future milestones, including the potential for Nyxol to be a “best in class” presbyopia drop. These forward-looking statements are based upon the Company’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation: (i) timing or ability for the company to achieve its targeted milestones; (ii) the success and timing of regulatory submissions and pre-clinical and clinical trials; (iii) regulatory requirements or developments; (iv) changes to clinical trial designs and regulatory pathways; (v) changes in capital resource requirements; (vi) risks related to the inability of the Company to obtain sufficient additional capital to continue to advance its product candidates and its preclinical programs; (vii) legislative, regulatory, political and economic developments, and (viii) the effects of COVID-19 on clinical programs and business operations. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors detailed in documents that have been and may be filed by the Company from time to time with the SEC. All forward-looking statements contained in this presentation speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.The Company makes no representation or warranty, express or implied, as to the accuracy or completeness of the information contained in or incorporated by reference into this presentation. Nothing contained in or incorporated by reference into this presentation is, or shall be relied upon as, a promise or representation by the Company as to the past or future. The Company assumes no responsibility for the accuracy or completeness of any such information. This presentation may not be reproduced or provided to any other person (other than your advisor) without our prior written consent. By accepting delivery of this presentation, you agree to the foregoing and agree to return this presentation and any documents related thereto and any copies thereof to us or to destroy the same if you do not make an investment in any securities. The information contain within this presentation shall not, except as hereinafter provided, without the prior written consent of the Company, be disclosed by you or your representatives in any manner whatsoever, in whole or in part, and shall not be used by you or your representatives other than for the purpose of evaluating the transaction described herein. By accepting delivery of this presentation you further acknowledge and agree aware of the restrictions imposed by the United States securities laws on the purchase or sale of securities by any person who has received material, nonpublic information from the issuer of the securities or any affiliate thereof and on the communication of such information to any other person when it is reasonably foreseeable that such other person is likely to purchase or sell such securities in reliance on such information for so long as the information remains material and non- public. This presentation also contains estimates and other statistical data made by independent parties and by us relating to market shares and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of such products.  November 6, 2020 
 
 3  Late Clinical Stage Company Targeting Large, Unmet Ophthalmic Markets  Significant Clinical Data andRegulatory Precedents  Significant IP Portfolio and Small Molecule CMC Advantages  Multiple Near-Term Data Catalysts with Capital Efficient Plan  Nyxol eye drops target multiple chronic and acute front of the eye indications addressing large markets: Reversal of Mydriasis (RM), Presbyopia (P) & Dim Light / Night Vision Disturbances (NVD)APX3330 tablets target chronic back of the eye indications: Diabetic Retinopathy (DR) and Diabetic Macular Edema (DME), a leading cause of blindness in diabetic patients  Nyxol and APX3330 achieved promising clinical data over multiple Phase 1, 2, and 3 trialsNyxol with > 330 patients treated across 9 trialsAPX3330 with > 340 patients treated across 11 trialsFDA End of Phase 2 meeting guidance for Nyxol (all indications) in May 2020  US and global issued patents thru 2034 for both assets; new 2039 Nyxol patent issued for presbyopiaStable, small-molecule drugsNyxol = single-use, preservative-free eye dropAPX3330 = oral pill  Initiated 4 late-stage trials (2 Phase 3, 2 Phase 2) with readouts expected in 2021-2022Reported positive P3 data in RM in 1Q21 with Nyxol NDA submission targeted late 2022Reported positive P2 data in Presbyopia in 2Q21 with plans to advance to P3 in 2022$22 million cash reported at the end of 3Q 2021 sufficient for operations through late 2022Analyst coverage by Cantor, Canaccord, Jones Trading, Alliance Global, Spartan, and Encode Ideas  Ocuphire OpportunityA Late-Stage Clinical Ophthalmic Biotech (Nasdaq Symbol: OCUP)  Nyxol® APX3330 
 
 4  Ocuphire Management TeamDecades of Biotech and Drug Development Experience        Mina Sooch, MBA  President & CEO and Founder        Drey Coleman VP, Clinical Operations        Amy Rabourn, CPA  VP, Finance              Charlie Hoffmann, MBA  VP Corporate Developmentand Operations        Mitch Brigell, PhDHead, Clinical Developmentand Strategy        Daniela Oniciu, PhD Global Head, R&D, Chemistry and Product Development        Ronil Patel, MSSenior Director BD andMarket Strategy  Chris Ernst Global Head, QA and Manufacturing        Barbara Withers, PhDVP, Clinical and Regulatory Strategy 
 
 5          Large Unmet Opportunities for the Aging EyeDeveloping Drugs to Treat Front & Back of the Eye Diseases  Source: GlobalData Market Research Report, 2020; Company Estimates for Market Size      Front Back  Nyxol®  APX3330  Reversal of Mydriasis US Market~100M pupil dilations per year in U.S. Opportunity$325M- $1BPresbyopiaU.S. Prevalence: ~120M$9B - $18BNight Vision DisturbancesU.S. Prevalence: ~16M adults$2B - $4B        $10+ to $20+B US Markets          $4 to $10B US Markets  Diabetic RetinopathyU.S. Prevalence:~ 7M  US Market Opportunity  $3B - $7BDiabetic Macular EdemaU.S. Prevalence: ~750K$1B - $3B           
 
 6              Product Candidate  Indication  Development Stage        Anticipated Milestones        Pre-clinical  Phase 1  Phase 2  Phase 3    Ocuphire-Focused Development  0.75% Nyxol®Eye Drop  Reversal of Mydriasis (RM)  Positive Data Readout        Initiated Phase 3 MIRA-2 trial 4Q20; Topline data reported in 1Q21 (n=185)Initiate Phase 3 MIRA-3 trial 2H21; Data expected in early 2022 (n=330)Initiate Pediatric trial 2H21;Data expected in early 2022 (n=20)    0.75% Nyxol® + Low- Dose 0.4% Pilocarpine Eye Drops  Presbyopia (P)  Positive Data Readout        Initiated Phase 2 VEGA-1 trial 1Q21; Topline data reported in 2Q21 (n=150)Initiate Phase 3 program in 1H22    0.75% Nyxol®Eye Drop  Dim Light or Night Vision Disturbances (NVD)  Recruiting        Initiated Phase 3 LYNX-1 trial 4Q20; Data expected in early 2022 (n=160)    APX3330Oral Pill  Diabetic Retinopathy (DR)/ Macular Edema (DME)  Recruiting        Initiated Phase 2 ZETA-1 trial Apr21; Data expected in 2H22 (n=100)  Partnering- Focused Development  APX2009 Intravitreal  DME, Wet Age-Related Macular Degeneration (wAMD)          Next steps: IND enabling studies (with partner funding)  Ocuphire Pipeline & Upcoming MilestonesMultiple Phase 3 & Phase 2 Clinical Data Readouts Anticipated over the Next Year  Note: 0.75% Nyxol (Phentolamine Ophthalmic Solution) is the same as 1% Nyxol (Phentolamine Mesylate Ophthalmic Solution)       
 
   7    11Phase 1 & Phase 2 Trials    >340Subjects Dosed    Exposure in Humans365Days    Patents to2034+    Extensive Development on Both Drug CandidatesWell-Controlled Phase 1, 2, and 3 Clinical Programs with MIRA-2 Data Leading the NDA Path  NCE Development Pathway  Studied in inflammation/hepatitis & cancer patients    9Phase 1, Phase 2,and Phase 3 Trials    330Subjects Dosed    Exposure in Humans28Days    Patents to2034+    505(b)(2) Development Pathway  Studied in multiple ocular refractive indications  Nyxol  APX3330 
 
 8        Nyxol®  Phentolamine Mesylate  Presbyopia      RM  Reversal of Mydriasis      NVD Night Vision Disturbances      P 
 
 9  Nyxol History & MOARationale for Differentiated Product Profile & 505(b)(2) Path      Nyxol’s active ingredient, phentolamine mesylate (PM), is currently approved for 2 indicationsPheochromocytoma (60+ years ago, Regitine®) – intravenous injectionReversal of oral anesthesia (10+ years ago, OraVerse®) – intramuscular injection  PM has been reformulated as a topical eye drop (Nyxol)Nyxol is a first-in-class non-selective α1 and α2 blocker product candidateMOA of relaxing the iris dilator muscle (α1)Redness is an on-target α1 effect on sclera vessels (transient, mild)      Phentolamine Mesylate  Dilates Blood Vessels (Vasodilation)α1: Smooth Muscle Blockade  Reduces Pupil Sizeα1: Iris Dilator Blockade                             
 
 10          Efficacy Data    Improving Vision↓ Pupil Size (moderate miotic)↑ Contrast Sensitivity (night)↑ Near Visual Acuity (light/dark)↑ Distance Visual Acuity              Safety Data    No Systemic EffectsNo Changes in Blood Pressure No Changes in Heart RateTolerated Topical EffectsMild / Transient / Reversible Eye RednessIOP Unchanged or Decreased↓ Intraocular Pressure (IOP) at Normal Baseline      Nyxol Product Candidate ProfileNovel Alpha 1/2 Blocker Eye Drop for Refractive Indications (505(b)(2) Pathway)  Nyxol: 0.75% Phentolamine Ophthalmic Solution Preservative Free, EDTA Free, and Stable  Chronic daily dosing of Nyxol at bedtime demonstratedno significant daytime redness and durability of effects for more than 24 hours 
 
 11        Nyxol®  Phentolamine Mesylate      NVD    P Presbyopia      RM Reversal of Mydriasis  Night Vision Disturbances    0.4%    + 
 
 12  Reversal of Mydriasis (RM) – Acute TreatmentAnnual Exams and Specialty Visits Involve Dilation to Monitor Eye Health  At many annual eye exams and specialty visits, pupils are pharmacologically dilated, impairing vision for 6-24 hoursDilated eyes:heightened sensitivity to lightinability to focusreading, working, and driving are difficulthalos and glare  The Problem  ~100M eye exams / year in US  No Current Commercially Available Treatments      RM  Source: GlobalData Market Research Report, 2020  I have to stay indoors. They say it only lasts a few hours, but it lasts all day, and it is very annoying.RM Patient, Age 51 
 
 13  Before After  Reversal of Mydriasis (RM) – Acute TreatmentSingle Use Indication Leveraging a Precedent Approval Pathway  Regulatory Precedent with Rev-Eyes (an alpha 1 blocker), approved by the FDA in 1990 but shortly thereafter discontinued (not for safety or efficacy reasons)Clinical Effect to potentially reduce pupil size and counteract the effect of mydriatic drugs (alpha agonists and cholinergic blockers) used to dilate the pupilConvenient and Stable eye drop given at the office that may allow vision to return to normal soonerTolerable with a minimal side effect profile (unlike cholinergic agonists such as pilocarpine)  Nyxol’s Potential Differentiated Solution  Seeking Treatment Findings    Patients likely to request reversal of dilation1  80%  Eye care providers likely to use reversal drops2  70%  Source: 1.GlobalData Market Research Report, 2020 – percentage includes those who answered moderately to highly likely (4-7 on a scale of 1-7) 2.GlobalData Market Research Report, 2020 – percentage includes those who answered moderately to highly likely (6-10 on a scale of 0-10)      RM 
 
     RM MIRA-2 Phase 3 Registration Design  Completed Randomized, Double-Masked, Placebo-Controlled, Parallel, One-Day Trial  MIRA-2  0.75% NyxolMydriatic Agent A, B, or C  12 USsites168target healthy subjects      Nyxol drop(s)(2 drops study eye, 1 drop fellow eye)      Mydriasis Time -1 HourPlaceboMydriatic Agent A, B, or C      Placebo drop(s)(2 drops study eye, 1 drop fellow eye)  TreatmentTime 0 (Max Dilation)      Primary: % of subjects (study eye) returning to baseline (within0.2 mm) pupil diameter (PD) at 90 min  Secondary:% of subjects returning to baseline at 30min, 1h, 2h, 3h, 4h, 6h, 24h (overall, by mydriatic agent, by iris color)Mean change in pupil diameter from mydriatic max at all timepoints (overall, by mydriatic agent, by iris color)Accommodation (Tropicamide/Paremyd)Safety and tolerability (redness)      Endpoints  Started and Completed Enrollment in 4Q20 – 185 Subjects  Topline Results Expected in 1Q21  Reported in March 2021  Eligibility Screening  Randomization  14 Mydriatic Agents 3:1:1 – 2.5% phenylephrine (alpha 1 agonist), 1% tropicamide (cholinergic blocker), Paremyd® (combination)                  1:1      RM 
 
 15  Primary Endpoint: % of Subjects Study Eye Returning to Baseline PD at 90 Min  Source: MIRA-2 Trial, mITT Population (same as Safety Population), *Data includes all three mydriatics (Phenylephrine, Tropicamide, Paremyd)  Nyxol Met the Primary & Secondary Endpoints at 90 Min; Additionally at 60 Min & All Subsequent Timepoints                                2%  7%  11%  18%  30%  45%  3%1%  59%  0%  20%  40%  60%  80%  100%  0.5  Percent of Subjects (Study Eye) (%)  1 1.5 2 3 4 6Time Post-Treatment with Nyxol/Placebo (Hours)    Placebo n=91    Nyxol n=94  p<0.000190%  p<0.000149%  p<0.0001  p<0.000180%  p<0.000182%  p<0.000128%                                                                                        3  4  5  6  7  8  9  6  Mean Pupil Diameter (Study Eye) (mm)  -1 0 0.5 1 1.5 2 3 4Time Post-Treatment with Nyxol/Placebo (Hours)    Nyxol n=94    Placebo n=91    Max pupil dilation, Treatment  Mydriatic          p<0.0001  p<0.0001  p<0.0001  p<0.0001  Nyxol Reduced More Subjects to Baseline Pupil Diameter (PD)% of Subjects Returning to ≤ 0.2 mm of Baseline  Nyxol Reduced PD Faster Across All Mydriatic Agents*Mean Pupil Diameter        MIRA-2 Phase 3 Trial  *Data include all three mydriatics (Phenylephrine, Tropicamide, Paremyd)  p<0.0001p<0.0001      RM   
 
 16                                                  3  4  5  6  7  8  9  6 24  Pupil Diameter of Study Eye (mm)  -1 0 0.5 1 1.5 2 3 4Time Post-Treatment with Nyxol/Placebo (Hours)  Tropicamide and Paremyd    Nyxol (n=38)    Placebo (n=36)                                                  3  4  5  6  7  8  9  3 4  6 24  Pupil Diameter of Study Eye (mm)  Time Post-Treatment with Nyxol/Placebo (Hours)  Phenylephrine    Nyxol n=56    Placebo n=55  Secondary Endpoint: Mean Pupil Diameter Over Time by Mydriatic AgentNyxol Reduced Pupil Diameter With All Mydriatic Agents; More Rapidly with Phenylephrine as Expected  Source: mITT Population, MIRA-2 Trial, Standard Error bars are shown.          Mydriatic      Max pupil dilation, Treatment          Max pupil dilation, Treatment  Mydriatic      MIRA-2 Phase 3 TrialNyxol More Rapidly Reduced PD in Subjects Across All 3 Mydriatic Agents  Mean Pupil Diameter      RM  p<0.0001  p<0.0001p<0.0001-1 0 0.5 1 1.5 2  p<0.0001  p<0.0001  p<0.0001  p<0.0001  p<0.0001  p<0.0001p<0.0001  p<0.0001  p<0.0001  p<0.0001  p<0.0001             
 
 17                                                                0.5  1  1.5  2  3  4  6  Placebo n=46  7%  4%  11%  15%  22%  35%  41%  Nyxol n=49  2%  25%  43%  47%  71%  69%  88%  0%  20%  40%  60%  80%  100%  Percent of Subjects (Study Eye) (%)  Time Post-Treatment with Nyxol/Placebo (Hours)    Placebo n=46    Nyxol n=49  Secondary Endpoint: % of Subjects Returning to Baseline PD by Iris Color  Source: MIRA-2 Trial mITT Population,, Data includes all three mydriatics (Phenylephrine, Tropicamide, Paremyd)  Evidence of Efficacy in Subjects with Either Light or Dark Irides, with a More Vigorous Response in Light Irides                                  0%  20%  40%  60%  80%  100%  P  0.5  1  1.5  2  3  4  6  Placebo n=45  0%  0%  2%  7%  13%  24%  49%  Nyxol n=45  0%  31%  56%  71%  89%  96%  93%  ercent of Subjects (Study Eye) (%)  Time Post-Treatment with Nyxol/Placebo (Hours)      Placebo n=45 Nyxol n=45  p<0.0001  p<0.0001  p<0.01   p<0.0001   p<0.0001  p<0.0001  p<0.0001  p<0.001  p<0.001p<0.001  p<0.01  p<0.0001  MIRA-2 Phase 3 TrialMore Subjects Returned to PD Baseline with Nyxol in Both Light and Dark IridesPercent of Subjects Returning to ≤ 0.2 mm of Baseline by Iris ColorLight Irides Dark Irides      RM 
 
 18    Secondary Endpoint: Accommodation And Time Savings  Nyxol Demonstrates a Faster Return to Baseline Accommodation and Shorter Dilation Time by 4-5 Hours  Source: MIRA-2 CSR table #14.2.3.2.1. PP population is the per protocol population.  Percent of Subjects with Unchanged Accommodation from Baseline (Tropicamide or Paremyd)  Study Eye, PP population      MIRA-2 Phase 3 Trial      RM                  16%  38%  66%  11%  77%  0%  10%  20%  30%  40%  50%  60%  70%  80%  90%  100%  0 2 6  Percent of Subjects (%)  Time Post-Treatment with Nyxol/Placebo (Hours)Note: Worsening of accommodation was defined as an amplitude decrease of greater than 1 diopter      Placebo (n=32) Nyxol (n=35)  * p<0.05  60*%              1.8  2.8  3.6  3.4  1.4  2.9  2.3  6.3  5.1  7.2  7.5  4.8  6.1  5.8  2  3  4  5  6  7  8  Hours      0 1Placebo Nyxol    Overall  Mydriatic Agent  Irides Color  Study Eyen=185  Non-Study Eyen=185  Phenylephrinen=97  Tropicamiden=34  Dark Iridesn=81  Light Iridesn=84  Paremydn=34        Average Time to Return to ≤ 0.2 mm of Baseline PD  Δt= 3.5 hrs    t  Δ = 3.2 hrs    Δt= 3.4 hrs    t  Δ = 4.1 hrs    t  Δ = 3.6 hrs    Δt= 2.3 hrs    t  Δ = 4.5 hrs 
 
 19      Summary of Positive MIRA-2 Phase 3 Results for Nyxol Eye Drops  Met primary endpoint at 90 minutes with high statistical significance with 2 drops of NyxolMet all key secondary endpoints with high statistical significance  Efficacy for all 3 mydriatic agents – phenylephrine, tropicamide, and Paremyd®Efficacy in both light and dark iris colorsEfficacy with only one Nyxol drop in non-study eye  Favorable safety profileNo serious AEs, no drop-outs from AEs, no systemic AEs were observed in ≥ 5% of subjectsMild, transient conjunctival hyperemia reported in the first hour and declined steadily thereafter. Baseline mean of 0.7, the mean hyperemia score increased by approximately 1.0 unit on CCLRU scale  mITT Population, MIRA-2 Trial  Sustained Efficacy with a Favorable Safety Profile in Reversing Mydriasis with Nyxol  Complete a second RM Phase 3 trial with increased subjects ~330 to also meet 24-hour safety population exposureComplete RM trial with 20 subjects ages 3 to 11 per pediatric planComplete registration batches with 1-year CMC stability and make commercial batches      Path to Registration  Submit NDA by Late 2022      Proposed IndicationThe treatment of pharmacologically induced mydriasis produced by adrenergic (e.g. phenylephrine) or parasympatholytic (e.g. tropicamide) agents, or a combination thereof.      RM 
 
 20  Reversal of Mydriasis (RM) Market OpportunityWith No Commercially Available Treatment, Nyxol May Provide Significant Revenue Potential  GlobalData market research reportVision Care Market Grows 2.4 Percent in 12-Months Ending September 2019. Vision Monday, January 20, 2020.  65% PatientsReport moderate to severe negative impact of dilated exams1  $5 - $20Price range surveyed for cash pay per patient with room for physician markup1          $325M - $1B+Estimated US RM Market Opportunity  100M+General and specialty eye exams per year1                          Tropicamide Alone 52%  Tropicamide and Phenylephrine 18%  Phenylephrine Alone 16%  Paremyd 9%  Cyclopentolate 5%  Physician’s Use of Mydriatic Agents1      $6B Eye Exam MarketExams, the third-largest category, grew faster than both prescription lenses and frames      Use of phenylephrine, tropicamide, Paremyd®, or combinations of such comprise nearly 95%  of dilating eye drops used by eyecare  professionals.1  OptoMap: Retinal screening for those wanting to avoid dilations but not a replacement for full dilated eye exam  $40-65 paid by patients      RM 
 
 21        Nyxol®  Phentolamine Mesylate      NVD    P  Presbyopia      RM  Night Vision Disturbances  Reversal of Mydriasis    0.4%    +   
 
 22  2021: The Time for Presbyopia DropsHeadlines From Academia and Industry Articles Thru the Year with an Early First Approval  Sources: Academic review articles, journals, and publications  “The correction of presbyopia remains ophthalmology’s ‘Holy Grail’…”-OIS  10/29/2021      P 
 
 23  Presbyopia – Chronic OpportunityAging Population Drives Demand for Alternatives to Reading Glasses & Very Large Market  Lens loses ability to change shape when viewing objects up close as we ageDependence on reading glasses for intermittent and prolonged useGrowing need for therapies that improve, rather than hinder, quality of life  Source: GlobalData Market Research Report, 2020  The Problem      P  120 MPatients  No Currently Approved Drug Therapies  Effectively everyone over 40 will have the problems with reading.Physician KOL  Seeking Treatment Findings    Patients requesting alternative to reading glasses  40%  Patients would consider an eye drop alternative  69%  ~$9-$18B Market OpportunityMarket Assumptions:Total patients - 120 million patients Price per month - $50+Patients considering eyedrops - ~50% Refills (Months) - 3 to 6 
 
 24  Presbyopia – Chronic OpportunityPupil Modulation Eye Drops May Replace Reading Glasses  “Pin-hole” effect of Nyxol and low dose pilocarpine may improve near vision by enhancing depth of field as validated by other devices/therapiesMore durable combination of two miotics affecting different muscles (iris dilator and sphincter) involved in pupil size modulationTolerable use with minimal side effects expected with chronic evening use of Nyxol and daytime use of fractional concentration of pilocarpineThis would just become part of my daily routine for my eyes to be able to see things up close. How convenient is that?Presbyopic Patient, Age 49  Retinaeyedoctor.com, GlobalData Market Research Report, 2020  Nyxol’s Potential Differentiated Solution      Large Pupil  Pin-hole Pupil  Near Far    In focus            In focus              P 
 
 25                    Product Profile: Nyxol ® + Low-Dose Pilocarpine (LDP) Combo  Moderate Action on Iris Dilator and Iris Sphincter Muscles for Near Vision Improvement  0.4%  0.75%Nyxol  0.4% LDP  Iris Dilator Muscle Inhibition    Iris Sphincter Muscle Activation          Phentolamine (alpha1/2 antagonist) approved non- ocular injectable indications decade(s) ago 505(b)(2)Novel MOA on iris dilator with 24+ hour durabilityModerate 1+mm pupil reductionNo daytime redness w/ chronic evening dosing NyxolWell-tolerated with no systemic effectsStable, preservative-free, single use vial  Pilocarpine (cholinergic agonist) approved decades agoKnown MOA on sphincter muscle with potent miotic effects at approved doses (1%, 2%, 4%)Chronic daytime dosing of LDPLow concentration avoids known tolerability issues:headache and browacherednessaccommodative spasm causing loss of distance vision especially at night  Source: 1) Nyxol® data from 8 completed trials; Pilocarpine Product label and Literature  1.5 to 2.5 mm PD reduction moves toward the pin-hole (2 to 2.5 mm, up to 3 mm)      Daytime drop    Evening drop                              P 
 
 26  Presbyopia VEGA-1 Phase 2 DesignRandomized, Double-Masked, Placebo-Controlled, Multi-Center One-Week Trial  Clinical trial NCT#04675151. DCNVA = distance-corrected near visual acuity . BCDVA = best corrected distance visual acuity    Endpoints          Primary: % of subjects with ≥ 3 lines of improvement in distance- corrected near visual acuity comparing Nyxol + LDP vs placebo alone at 1 hourSecondary:% of subjects with ≥ 2 and ≥ 3 lines gained at time points from 30 min to 6 hours in photopic lighting comparing Nyxol + LDP vs placebo, Nyxol alone, and LDP aloneNo loss of distance visionPupil diameter at time pointsSafety and tolerability (redness)      Visit 1          VEGA-1  Randomization  4 arms      0.75% Nyxol  Placebo  17 US sites150presbyopic patients  Visit 2(3 – 6 Days Later)                  Treatment Arms  Nyxol + LDP  LDP Drop      Nyxol      Baseline          Nyxol Alone  No Treatment      Nyxol      Baseline          LDP Alone  LDP Drop      Placebo      Baseline          Placebo Alone  No Treatment      Placebo      BaselineScreening      Evening Dosing (3-4 doses)  Males or females ≥ 40 and ≤ 64 years of ageBCDVA of 0.0 LogMAR(20/20 Snellen equivalent) or better in each eye under photopic conditionsDCNVA of 0.4 LogMAR (20/50 Snellen equivalent) or worse in photopic conditions in each eye & binocularly  Eligibility Criteria      P  Phase 2 Enrollment Completed Feb to May 2021 – 150 SubjectsReported Topline Results End of 2Q21 
 
 27    79%  90%80%70%60%50%40%30%20%10%0%  Percent of Subjects (%)  Secondary Endpoint: Percent of Subjects with ≥ 10 Letters DCNVA Improvement from Baseline Binocular (PP Population)      1Time (Hours)Placebo (n=43) Nyxol+LDP (n=43)        Primary Endpoint: % of Subjects ≥ 15 Letter Gain in Photopic DCNVA at 1 HourPrimary Endpoint Was Significantly Met for Nyxol + LDP Gaining ≥ 15 Letters Near Vision  VEGA-1 Phase 2 Trial            61%   28%   90%80%70%60%50%40%30%20%10%0%  Percent of Subjetcts (%)  Primary Endpoint: Percent of Subjects with ≥ 15 Letters DCNVA Improvement from Baseline Binocular (PP Population)      1Time (Hours)Placebo (n=43) Nyxol+LDP (n=43)  p=0.003  33%Placebo  Adjusted  Responders    p=0.006                      49%        30%          PlaceboAdjusted          Responder                                s    Source: VEGA-1 TLR Table 14.2.1.2 %of Subjects With Improvement From Baseline in Photopic DCNVA by Time Point (PP Population). 15 letters is 3 lines and 10 letters is 2 lines.  Note: PP population differs from mITT by only one subject; results were essentially identical.      P 
 
 28  Efficacy Endpoints: % of Subjects ≥ 15 Letter DCNVA Gain Across TimepointsNyxol + LDP had Strong Response with ≥ 15 Letter Near Gain from 30 Minutes to 6 Hours  Source: VEGA-1 TLR Table 14.2.1.2 Percent of Subjects with Improvement From Baseline in Photopic DCNVA by Time Point (PP Population). 15 letters is 3 lines.                                                                              Percent of Subjects (%)                      VEGA-1 Phase 2 Trial    Percent of Subjects with ≥ 15 Letters Binocular Photopic DCNVA Improvement from Baseline70% p=<0.0001 Durable benefitp=<0.0001 p=0.003 63% over 6 hours61% 61%60%Nyxol alone effect(~12 hr data) p=0.02 p=0.0250% 47% 47%p=0.0640% p=0.09 37%33%30% 28%21% 21% 19%20% 16% 14% 16%10%0%0 0.5 1 2 3 4 6Primary EndpointRapid onset Time (Hours)of efficacy Placebo (n=43) Nyxol+LDP (n=43)          P 
 
 29  2nd Endpoint: % of Subjects ≥ 15 Letter Gain In Near & < 5 Letter Loss In Distance  Source: VEGA-1 TLR Table 14.2.2.2 Percent of Subjects with >= 15 Letters of Improvement in Photopic DCNVA and < 5 Letters of Loss in Photopic Binocular BCDVA by Time Point (PP Population)  Phase 3 Approval Endpoint Confirmed Greater Efficacy of Combo over Components at Multiple Timepoints                                                            14%  14%  61%  61%  63%  33%  26%  42%  10%0%  20%  30%  40%  50%  60%  70%  0.5  1  2  Percent of Subjects (%)  Percent of Subjects with 15 Letter Improvement in DCNVA and < 5 Letter Loss in BCDVA Binocular    Placebo (n=43)      Time (Hours)Nyxol+LDP (n=43) Nyxol (n=30)    LDP (n=31)  p=<0.0001  p=0.03  p=0.0130%  p=0.008  p=0.00428%  p=0.06 39%   p=<0.0001  p=0.2  p=0.000920%  Statistics Compared to Nyxol+LDP arm Powered for comparison to placebo whereas comparison to component arms were designed to inform the Phase 3 sample size        VEGA-1 Phase 2 Trial      P    Even with a small sample size, combination arm provided statistically meaningful results at  30 min and 2 hours  vs. LDP and Nyxol  alone arms 
 
                                                                                   30  Secondary Endpoint: Mean Pupil Diameter Over Time  Source: VEGA-1 TLR Table 14.2.12.1 Observed Values and Change from Baseline in Photopic Pupil Diameter by Time Point (PP Population)  4.3          4.5      4.4      4.3                  4.2      3.2      2.4      2.1      2.3      2.5      2.7      2.9      4.8      3.1      3.2      3.2      3.4          3.3      3.3      4.4      4.3      3.0      2.5      2.7      3.1      3.3      1.0  2.0  3.0  4.0  5.0  -1  0  1  2  3  4  5  6  Mean Pupil Diameter (mm)  Best Eye Mean Pupil Diameter  Time (Hours)Placebo (n=43) Nyxol+LDP (n=43) Nyxol (n=30) LDP (n=31)  *** 4.5  ***  ***  ******  ***  ***  **  ***  ***  **  *** 4.4  *** 4.4  *** 3.3***  *** 4.6  **  *** 3.6        Daily Evening Nyxol Dosing 12 hr minimum interval to Time 0    Baseline  ******    Nyxol+LDP arm  statistically significant compared to all arms  **p<0.01***p<0.0001        Achieved Pupil Size ~2mm in Nyxol+LDP Consistent with 3-line Improvement in Near VisionVEGA-1 Phase 2 Trial      P 
 
 31  Secondary Endpoint: Safety FindingsNyxol + LDP Combination Was Well Tolerated with a Favorable Safety Profile  Source: VEGA-1 Study Results (Safety Population, n=150); Only a single subject difference between mITT (n=148) and PP population (n=147)  No serious AEs, almost all AEs were mild0% headaches or brow aches reported for Nyxol+LDP arm  ≤ 5% mild, transient conjunctival hyperemia AEs in Nyxol+LDP armNo change in distance vision for Nyxol + LDP arm0% had ≤ 5 letter distance loss in photopic lightingOnly 5% distance loss in mesopic lightingNo change in IOP  Conjunctival Hyperemia CCLRU Scale  Nyxol + LDP and LDP aloneOnly transient 0.5 point mean increase      P 
 
 32  Product Attributes*  Nyxol+LDP compared to VUITYTM  Efficacy (all time-points)  ✓+  Safety: Maintain Distance Vision (especially at night)  ✓+  Safety: Tolerability (no headaches)  ✓+  Durability (at least 6 hours)  ✓+  Fast Onset (within 30 mins)  ✓+  Convenience (daily drops)  ✓  Tunable Pupil Modulation  ✓+  ASCRS (July 2021) Abstract# 76645 (Phase 2) and 74336 (Phase 3) and VUITYTM Label✓+- Indicates better compared to Vuity- Indicates comparable to Allergan/AbbVie based on Phase 3 BID dosing (NCT04983589)  Potential ‘Best in Class’ Presbyopia DropNyxol+LDP Combination Data Outperforms in Efficacy, Safety, Durability and Onset      P  Nyxol’s Potential Differentiated Solution 
 
 33  Presbyopia Eye Drops Competitive Landscape  Corporate Websites, Grzybowski, A, Markeviciute A, Zemaitiene R. A Review of Pharmacological Presbyopia Treatment. 2020  Validation of Pupil Modulating Drops Achieving Pin-Hole Effect & Efficacy, Many with Pilocarpine  Pupil modulation MOA    Combination drugs        Soften lens MOA  Phase 3  Phase 2  Phase 1  Allergan (VUITYTM;1.25% pilo)  Orasis (CSF-1;Low dose pilo)  Ocuphire (0.75% Nyxol+ 0.4% pilo)  carbachol)  Other Cholinergic Agonists*Visus (Brimochol®; brimonidine +  Cholinergic Agonist* (pilocarpine)  Lenz  (PRX-100;aceclidine)  Eyenovia (MicroLine; 1 or 2% pilo)  Novartis (EV-06)          Alpha Antagonist & pilocarpine*      P  NDA  *act on sphincter and ciliary muscles in dose- dependent manner  Ocuphire is differentiated by using both the dilator and sphincter muscles moderately to reach a pin-hole pupil size  Next Steps: Advance into Phase 3 Presbyopia Registration Trials in 1H 2022 Towards a Potential NDA Filing in 2023 
 
 34        Nyxol®  Phentolamine Mesylate      NVD    P  Presbyopia      RM  Night Vision Disturbances  Reversal of Mydriasis    0.4%    +   
 
 35  Moderate-to-Severe NVDs  US Patients  Night Myopia  10.8M  Cortical Cataracts  4.1M  Post-LASIK  500k  Post-IOL Implant  300k  Total  ~16M  Night Vision Disturbances (NVD) – Chronic OpportunityImperfections in the Eye Affect Night Vision in Millions  Peripheral imperfections scatter light when pupils enlarge in dim light, causing halos, starbursts, and glare that impair visionThe imperfections may be caused by LASIK surgery, IOL implants, certain types of cataracts (cortical), and natural reasons (especially with age)Symptoms cannot be properly corrected by any type of lens (reading glasses, contact lenses) or surgical procedures  Source: GlobalData Market Research Report, 2020  The Problem  No Currently Approved Therapies      NVD  I’m no longer comfortable driving at night, especially with my son in the car. I have a hard time playing beach volleyball in the evenings due to the bright lights at the courts.Post-LASIK, Age 42 
 
 36  Night Vision Disturbances (NVD) – Chronic OpportunityPeripheral Optical Imperfections Allowing Pupil Modulation as a Solution  Moderate Decrease in Pupil Size for scattered light gets blocked by the irisClinical Effect to potentially improve low contrast night vision as seen in trialsTolerable with a minimal side effect profileConvenient and Durable with chronic once-daily evening dose  Nyxol’s Potential Differentiated Solution      After  Before  Once there is a drug and a category, that’s when they start looking for the disease.Physician KOL  Seeking Treatment Findings    Patients willing to try a new eye drop treatment  67%  Patients avoiding driving at night  25%      NVD 
 
 37          NVD LYNX-1 Phase 3 Registration DesignOngoing Randomized, Double-Masked, Placebo-Controlled Two-Week Trial  LYNX-1          Endpoints    Primary: % of subjects with≥ 3 lines of improvement in mesopic low contrast best- corrected distance visual acuity (Day 8)Secondary (Days 8 & 15):Pupil diameterVisual acuity measures (distance and near)Safety and tolerability (redness)      Eligibility Screening  Randomization  1:1              0.75% Nyxoldaily evening dose (14 days)      daily evening dose (14 days)  Placebo  20 US sites~160 patients with NVD  Phase 3 Initiated in Late 4Q20  Top Line Expected Early 2022      NVD 
 
 38                                  -0.07-2%  -0.05-0.5%  -0.11-1%        -0.99-20%  -1.00-21%  -0.88-19%  -1.4  -1.2  -1  -0.8  -0.6  -0.4  -0.2  0  0.2  Day 8  Day 15  Day 16  Pupil Diameter Change from Baseline ANCOVA (mm and %)    Placebo (n = 20)        14-day Daily Evening Dosing, Last Dose on Day 14        ORION-1 Phase 2 Trial  Nyxol Demonstrated Clinical Effect in NVDKey Endpoints Observed in Multiple Phase 2 Trials  Source: NYXG-201  Durable > 24-hour Pupil Modulation EffectPupil Diameter Change from Baseline in Mesopic Conditions (Study Eye)Baseline Pupil Diameter: Placebo 4.6mm, Nyxol 4.7mm                Percent of Subject Eyes    NYX-SNV Phase 2 Trial          Improved Low Contrast Distance Visual Acuity*% of Eyes with Mesopic Low Contrast Visual Acuity Improvement80% p=0.02969% Placebo n=16Nyxol n=3260%p=0.0440% 34%31% p=0.1619%20%6%0%0%≥ 1 line ≥ 2 lines ≥ 3 linesSource NYX-SNV        *NYX-SNV trial was small and not designed for a statistical 3-line improvement in low-contrast visual acuity; the ~20% effect was used for powering and sizing of Phase 3 trial  p = 0.0002  1% Nyxol (n = 19)p = 0.0001  p = 0.0004      NVD 
 
 39        APX3330  APX3330      DR Diabetic Retinopathy      DME Diabetic Macular Edema      wAMD    Wet Age-Related Macular Degeneration 
 
 40  Large, Unmet Need in Diabetic Eye Diseases (US)    DR  ~7.7M Patients  DME  ~750K Patients  Diabetic Retinopathy & Macular EdemaNon-Injectable Alternative Therapies are Needed For Earlier Stages of Disease  Diabetic retinopathy (DR) and diabetic macular edema (DME) are a leading cause of vision loss worldwideDiabetes damages small blood vessels within the eye causing leakage, oxygen starvation, and abnormal vessel growthDR patients are not routinely treated with approved injectable anti-VEGF drugsDR progresses resulting in vision lossCurrent treatment for DME are not satisfactory25% non-responders50% partial responders to anti-VEGF drugs  Sources: Global Market Insights Report 2019-2025, Market Watch 2019 Report, Gene.com Retinal Diseases Fact Sheet  The Problem  Limited Retina Treatment Options for Diabetics  DR DME      DR      DME 
 
 41  APX3330 History and Ref-1 Inhibition MechanismRef-1 Involved in Multiple Key Pathways that Contribute to Diabetic Retinopathy and DME  Mechanism of Action – Ref-1 Inhibition  Hypoxia  Ref-1  HIF-1α  VEGF(Signaling Cascade)  Inflammation  Ref-1  NF-κB  Other Growth Factors (Signaling Cascade)  TNF-αChemokines  Neovascularization                                  Lucentis® EYLEA®  Anti-VEGF        Steroids                    APX3330  Logsdon et al (2018), Li et al (2014).  Ref-1 (reduction-oxidation effector factor-1) is a novel target discovered by Dr. Mark R. Kelley at Indiana University School of MedicineAPX3330 is a small molecule oral drug candidate and a first-in-class inhibitor of Ref-1APX3330 previously developed by Eisai for multiple hepatic inflammatory indications and later by Apexian for advanced solid tumors– Similar oncology origin as approved anti-VEGFsMOA uniquely decreases both abnormal angiogenesis and inflammation by blocking pathways downstream of Ref-1          DR      DME 
 
 42  APX3330 Down-Regulates VEGF Protein and Anti-Inflammatory Cytokines  In Vivo and In Vitro Evidence of APX Dual Pathway Mechanism of Action  Treatment of APX3330 (10mg/kg, oral gavage) in rats with type 1 diabetes and induced stroke shows a significant decrease of VEGF signaling.Increased VEGF is a hallmark of uncontrolled neovascularization and inflammation in diabetic retinopathies; current approved treatments successfully decrease VEGF levels in the eye.    Tao Yan et al. APX3330 Promotes Neurorestorative effects after stroke in type one diabetic rats. Aging and Disease. Vol 9, Oct 2018Apurinic/Apyrimidinic endonuclease 1 regulates inflammatory response in macrophages. Jedinak A, Dudhgaonkar S, Kelley MR, Sliva D. Anticancer Res. 2011 Feb;31(2):379-85. PMID: 21378315  In vitro APX3330 suppresses pro-inflammatory cytokines in LPS stimulated murine macrophage cell lines known to be involved in macular degeneration:  TNF-α is a potent cytokine that enhances secretion of VEGF-A and VEGF-B by human choroidal fibroblast cells. J Cell Physiol. 2011Genetic ablation of IL-6 led to significant suppression of AMD (murine CNV model). Am J Pathol. 2007  APX3330 Reduces VEGF Protein in the Brain of Preclinical Models  APX3330 Reduces Pro-inflammatory Cytokinesin Murine Cell Lines Involved in Macular Degeneration      DR      DME 
 
 43  Preclinical Data: Oral APX3330 Blocks NeovascularizationLesion Volume Decrease with Oral APX3330 in Murine Laser CNV Model Similar to EYLEA® Data  Silva et al. Oral APX3330 treatment reduces L-CNV lesions in preclinical mouse model and confirms Phase 2 DR/DME clinical dose with sufficient distribution to human retina using PBPK modeling. Presented at the ARVO 2021 Annual MeetingPublished data on EYLEA    -44%  EYLEA      L-CNV Mouse Retina Model          APX3330Lesion Size and Corresponding Fluorescent Stains in L-CNV Models Treated with APX3330 at 25 mg/kg oral gavageVehicle 25 mg/kg 50 mg/kg APX3330 Gavage OCTLesion Volume-55%Silva et al, 2021            L-CNV Mouse Retina Model      DR      DME 
 
 44  Apexian preclinical dataEisai preclinical dataSilva et al. Oral APX3330 treatment reduces L-CNV lesions in preclinical mouse model and confirms Phase 2 DR/DME clinical dose with sufficient distribution to human retina using PBPK modeling. Presented at the ARVO 2021 Annual Meeting    Phase 1 PK Clinical Data          Human Drug Exposure Multiple Times Higher than Mouse Efficacious LevelsHuman Pharmacokinetics of APX3330 at 120 mg/dayHuman 120 mg/dayMice 25 mg/kgSource: Eisai/Apexian Human PK data                  Human  Mouse  Rat  10 mg/kg APX3330 oral gavage measured in rat eye2  300 mg BID (600 mg/day total)Established PBPK model predicts APX3330 reaches sufficient human retinal concentrations3  25 mg/kg APX3330 oral gavage measured in mouse retina1  Phase 1/2 Clinical Trials: PK Data Supporting the ZETA-1 TrialAPX3330 is Bioavailable and Reaches the Retina via Oral Administration  Does oral administration of APX3330 reach the retina in sufficient concentration?        DR      DME 
 
 45        APX3330 Product Candidate Profile for Multiple Retinal IndicationsFirst-in-Class Ref-1 Inhibitor with Favorable Human Safety Data for Retinal Indications          Expected Efficacy Data    Improving Eye Health in Diabetics↓ Inflammation↓ Abnormal AngiogenesisEnhance Compliance & ExposureOral pill may reduce the burden of frequent anti-VEGF injections              Safety Data    Few Systemic Adverse Effects< 5% Mild Gastrointestinal (diarrhea)< 5% Mild Skin Rash (reversible)Lack of Significant Acute Neurologic, Cardiovascular, Liver, or Pulmonary toxicityNo Ocular EffectsNo observed ocular AEs      APX3330: Well-tolerated Oral Dose up to 600mg/day  Twice a day dosing of APX3330 being developed to provide steady state effectiveness with a tolerable chronic safety profile      DR      DME 
 
 46  DR/DME ZETA-1 Phase 2b DesignOngoing, Randomized, Double-Masked, Placebo-Controlled 24-Week Trial (Similar to Eylea Pivotal P3 DR Trial)  NPDR = non-proliferative diabetic retinopathy (which includes non centrally involved diabetic macular edema) PDR = proliferative diabetic retinopathy (which includes non centrally involved diabetic macular edema)          ZETA-1  Eligibility Screening  Randomization  1:1              APX3330 600mgTwice daily oral dose (24 weeks)      Twice daily oral dose (24 weeks)  Placebo  20 US sites~100 patients with moderate- to-severe NPDR and mild PDR      Primary: % of subjects with a ≥2 step improvement on the DRSS (DiabeticRetinopathy Severity Scale) score at week 24Secondary:Central subfield thickness (CST)BCDVA (ETDRS)DRSS change at week 12Rescue subjectsSafety and tolerabilityExploratory:Labs / PK      Endpoints  Phase 2b Start Initiated in April 2021  Top Line Expected in 2H22      DR      DME 
 
 47  Innovative Approach for Retinal Diseases with APX PlatformAPX3330 May Treat Patients Across the Spectrum of Retinal Diseases  Potential First Oral Rx for Retina DiseasesFirst-line earlier intervention for the diabetic eyeAdd-on therapy to current anti-VEGF treatmentsProven Novel MechanismMay decrease both inflammation and angiogenesisConvenient Daily RegimentFavorable Oral Safety ProfileAs seen in 11 completed Phase 1 and Phase 2 clinical trialsImprove Patient CompliancePotentially alleviate the frequent burden of injections  Potential Differentiated Solution  DR  DME  Wet AMD  Dry AMD  RVO  GA  APX3330  Current anti-VEGF treatments  APX2009 APX2014 APX3330(Local Delivery)        DR      DME 
 
 48    Boards and Milestones 
 
 49  Ed Holland, MDLoyola University Chicago  Jay Pepose, MD, PhD UCLA  Thomas Samuelson, MD University of Minnesota  Paul Karpecki, OD Indiana University  Eliot Lazar, MDGeorgetown University  Marguerite McDonald, MD Columbia University  David Boyer, MD Chicago Medical School  Gerald Horn, MD University of IllinoisCo-Founder Ocularis/Nyxol Past MAB Member  Mark Kelley, PhD Indiana UniversityCo-Founder Apexian/APX3330    Ocuphire's World-Class Medical Advisory BoardFortunate for the Insights of Leading KOLs & Drug Candidate Co-Founders  elCON Medical  Michael Allingham, MD, PhD University of North Carolina  Peter Kaiser, MD Harvard Medical School  Jeffrey Heier, MD Boston University  Y. Ralph Chu, MD Northwestern University  Douglas Devries, OD University of Nevada  David Brown, MD Baylor University  Richard Lindstrom, MD University of Minnesota 
 
 50              Ocuphire Board of DirectorsSeasoned Directors with Decades of Drug Development, M&A/Financings, and Ophthalmology                    Sean Ainsworth, MBALead Independent Director,Board Director  James Manuso, PhD/MBABoard Director  Jay Pepose, MD, PhDBoard Director  Richard Rodgers, MBABoard Director        Susan Benton, MBABoard Director  Cam Gallagher, MBAChair, Board Director        Mina Sooch, MBA  Vice-Chair, Board DirectorPresident & CEO 
 
 51            2021 to 2022 Ocuphire Cadence of MilestonesMultiple Data Catalysts On Path To NDA(s)  Ongoing Partnering Discussions with Leading Ophthalmic Companies (including European and Asian Players)  2021 2022          Report Phase 3 Data for NVD        Report 2nd Phase 3 Data for RM        Report Pediatric Data in RM        Submit Nyxol NDA for RM        Report Phase 2 Data for DR/DME        Initiate Two Phase 3 Presbyopia Trials            Report Positive Phase 3 Data for RM (MIRA-2)  Report Positive Phase 2 Data for Presbyopia (VEGA-1)  New Patent Claims for Presbyopia  ASCRS 2021 Presentation for MIRA-2 & VEGA-1  Manufacture 3xRegistration Batches for Nyxol Blow-Fill-Seal (BFS) Eye Drops  Initiate 2nd Phase 3 RM and Pediatric RM trial Initiate Phase 3 Chronic Safety Trial  Early 2022 
 
 52  Recent FDA Ophthalmology Drug ApprovalsFDA Record Number of Drugs Approved for Front and Back of the Eye in 2021  Source: Company websites, 2020 10K annual reports, Q2 2021 quarterly reports          Company  Drug  Indication  Date  Status    Cyclosporine Topical Opthalmic Emulision  Severe Vernal Keratoconjunctivits  June 2021  New Product Approval    OC-01 Nasal Spray  Dry Eye Disease  October 2021  New Product Approval    DextenzTM  Ocular Itching Associated with Allergic Conjunctivitis  October 2021  sNDAApproved    XipereTM  Macular Edema associated with Uveitis  October 2021  New Product Approval    MydCombiTM  Fixed combination mydriatic microdose system  October 2021  CRL, now drug/device classifcaiton    SusvimoTM  Wet-AMD  October 2021  New Product Approval    Vuity TM  Presbyopia  October 2021(10-29-21)  Approved Two months inadvance 
 
 53  OCUP – Market SnapshotSufficient Cash Runway Through 2022  Source: FactSet  Ticker  OCUP    Price  $4.02  Close on 11-1-21  Market Cap  ~$70 M  As of 11-1-21  Common Shares Outstanding  17.3 M  As of 9-30-21  Cash  $22.2 M  As of 9-30-21  Cash Runway  Sufficient through 2022  Guidance as of 9-30-21  Average Daily Volume  ~200 K  As of 11-1-21  Short Interest  ~445K; <3% of Float  As of 11-1-21  Research Analyst - Institutional Coverage on OCUP    James Molloy  Alliance Global Partners  John Newman  Canaccord Genuity  Kristen Kluska  Cantor Fitzgerald  Prakhar Agrawal  Jones Trading 
 
     Restore Vision & Clarity  www.ocuphire.com [email protected] 
 
 55    Appendix 
 
 56  NVD Endpoint: 5% Low Contrast Visual Acuity (LCVA) ChartFDA Accepted Endpoint for Contrast Sensitivity Assessment  Precision Vision          Before Treatment* 3 Lines Improvement Illustration                Primary Endpoint of Nyxol LYNX-1 TrialPercent of subjects with ≥ 3 lines of improvement in mesopic low contrast best-corrected distance visual acuity(7 days)  * Inclusion Criteria includes subjects with baseline mesopic LCVA of 20/100 or worse     
 
 57    DRSSScore  1(10)  2(20)  3(35)  4(43)  5, 6(47, 53)    7 – 13                (60  , 61,  65,                71, 75,85,90)    Description  DR Absent  Micro- aneurysm only  Mild NPDR  Moderate NPDR  Moderately Severe NPDR  PMod  DR – Mild, erate, and Severe    Retinal Image  Healthy blood vessels with no bulges  Small bulges in blood vessel walls as well as other signs in the retina  More changes in the blood vessels in the retina and small spots of blood can become more visible  More blood vessels in larger areas of the retina show changes  Many of the blood vessels in the retina show visible changes  Incr of n bl  eased growth ew, damaged ood vessels    DR/DME Endpoint: Diabetic Retinopathy Severity Scale (DRSS)FDA Accepted Endpoint for DR (EYLEA® in PANORAMA Pivotal Trial)  EYLEA Product Pamphlet ®  Patientsincluded in the ZETA-1 Trial  Primary Endpoint of APX3330ZETA-1 TrialPercent of patients with a ≥ 2 step improvement on the DRSS score at week 24  A 13-point Scale Outlining the Various Stages of Diabetic Retinopathy